Application No.: 10/759,293 Docket No.: CELLTH 3.0-003 CONT CONT XI

IN THE CLAIMS

- 1. (original) A kit, comprising arsenic trioxide and instructions for the administration of said arsenic trioxide to a patient diagnosed with acute promyelocytic leukemia, comprising delivering a therapeutically effective dosage amount of about 0.15 mg/kg of said arsenic trioxide wherein said amount is based upon the weight of said patient.
- 2. (original) The kit of claim 1, further comprising instructions wherein said arsenic trioxide is delivered to said patient until bone marrow remission, which constitutes a first administration.
- 3. (original) The kit of claim 2, further comprising instructions for a second administration of said arsenic trioxide, wherein said second administration comprises a therapeutically effective dosage amount of about 0.15 mg/kg of said arsenic trioxide for 25 doses.
- 4. (original) The kit of claim 3, wherein further comprising instructions wherein said second administration is administered 3 to 6 weeks after the first administration.
- 5. (original) The kit of claim 4, further comprising instructions wherein said second administration is administered for up to five weeks.
- 6. (original) The kit of claim 5, further comprising instructions wherein said second administration is administered at five doses per week.
- 7. (original) The kit of claim 3, further comprising instructions for repeating said second administration.
- 8. (original) The kit of claim 7, further comprising instructions wherein said second administration is repeated every 3 to 6 weeks.
- 9. (original) The kit of claim 8, further comprising instructions wherein said second administration is

Application No.: 10/759,293 Docket No.: CELLTH 3.0-003 CONT CONT XI

repeated until a total of between two and ten cycles of said second administration are completed.

- 10. (original) The kit of claim 9, further comprising instructions for repeating said second administration until a total of two cycles of said second administration are completed.
- 11. (original) The kit of claim 9, further comprising instructions for repeating said second administration until a total of ten cycles of said second administration are completed.
- 12. (original) The kit of claim 1, further comprising instructions wherein said arsenic trioxide is delivered to said patient for sixty days, which constitutes a first administration.
- 13. (original) The kit of claim 12, further comprising instructions for a second administration of said arsenic trioxide, wherein said second administration comprises a therapeutically effective dosage amount of about 0.15 mg/kg of arsenic trioxide for 25 doses.
- 14. (original) The kit of claim 13, wherein further comprising instructions wherein said second administration is administered 3 to 6 weeks after the first administration.
- 15. (original) The kit of claim 14, further comprising instructions wherein said second administration is administered for up to five weeks.
- 16. (original) The kit of claim 15, further comprising instructions wherein said second administration is administered at five doses per week.
- 17. (original) The kit of claim 13, further comprising instructions for repeating said second administration.

Application No.: 10/759,293 Docket No.: CELLTH 3.0-003 CONT CONT XI

18. (original) The kit of claim 17, further comprising instructions wherein said second administration is repeated every 3 to 6 weeks.

- 19. (original) The kit of claim 18, further comprising instructions wherein said second administration is repeated until a total of between two and ten cycles of said second administration are completed.
- 20. (original) The kit of claim 19, further comprising instructions for repeating said second administration until a total of two cycles of said second administration are completed.
- 21. (original) The kit of claim 19, further comprising instructions for repeating said second administration until a total of ten cycles of said second administration are completed.